MT1-MMP

Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day

Retrieved on: 
Thursday, December 14, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Webcast, MT1-MMP, Peripheral neuropathy, Brain, Safety, Immune system, Cervical cancer, Food, Therapy, Toxicity, Head, Diabetic neuropathy, Nobel Prize, Patient, CD137, Bicycle, FDA, Non-small-cell lung cancer, Pembrolizumab, Neoplasm, Ionis, Investigational New Drug, Brentuximab vedotin, MUC, ORR, Ovary, Anal cancer, Cancer, Ovarian cancer, Toxic leukoencephalopathy, Pain, R, Drug combination, EV, Central nervous system, TNBC, NSCLC, BRC, Pharmaceutical industry, Vaccine, Birth control, Medical imaging, Thromboxane A2

“In totality, the data support the emerging differentiated profile of our Bicycle® molecules, paving the way to deliver best-in-class or first-in-class therapies for many cancers.

Key Points: 
  • “In totality, the data support the emerging differentiated profile of our Bicycle® molecules, paving the way to deliver best-in-class or first-in-class therapies for many cancers.
  • BT8009 is a Nectin-4 Bicycle toxin conjugate (BTC®) designed to overcome the significant toxicity associated with other toxin conjugate approaches.
  • Over 2024, Bicycle Therapeutics intends to generate early human imaging data from its wholly owned BRC pipeline.
  • Bicycle Therapeutics will continue to develop Bicycle® molecules to address disease outside of oncology through innovative partnerships.

Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) Programs at the SITC 37th Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Bicycle, Annual general meeting, Date, Immunotherapy, CD137, Drug development, Therapy, NASDAQ, Thromboxane A2, BTC, Cancer research, Biotechnology, Time, Industry, Society, MT1-MMP, SITC, Fine chemical, Animal

Details on Bicycles poster presentations at SITC are as follows:

Key Points: 
  • Details on Bicycles poster presentations at SITC are as follows:
    Date and Time: Thursday, November 10 at 9 a.m.
  • ET
    Presenters: Kristin Hurov and Lia Luus, Bicycle Therapeutics
    Date and Time: Friday, November 11 at 9 a.m.
  • Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry.
  • Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA.

Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update

Retrieved on: 
Tuesday, November 8, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, Neoplasm, Ovarian cancer, NASDAQ, BTC, U.S. Securities and Exchange Commission, CPI, Patient, SEC, Bicycle, Private Securities Litigation Reform Act, Biotechnology, Thromboxane A2, Clinical trial, NSCLC, RECIST, MT1-MMP, Large-cell lung carcinoma, Forward-looking statement, CD137, Drug development, MRCP, Cisplatin, Kidney, Cancer research, Cell, Squamous cell carcinoma, Therapy, Risk, Phase II, Security (finance), Pharmaceutical industry, UC, Phase

Dosing our first patient in the Phase II expansion portion of the BT8009 trial is a key development milestone for Bicycle, said Kevin Lee, Ph.D., Chief Executive Officer.

Key Points: 
  • Dosing our first patient in the Phase II expansion portion of the BT8009 trial is a key development milestone for Bicycle, said Kevin Lee, Ph.D., Chief Executive Officer.
  • Two doses have been selected as the recommended Phase II doses (RP2Ds): 5mg/m2 weekly and 7.5mg/m2 2-weeks on, 1-week off (over a 21-day cycle).
  • The Phase II multi-center, open label trial will evaluate BT8009 administered at the RP2Ds of 5mg/m2 and 7.5mg/m2.
  • The ongoing dose expansion includes cohorts evaluating the activity of BT8009 in CPI combination cohorts as well as in cohorts of patients with renal impairment.

Bicycle Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Friday, November 4, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Therapy, CD137, Biotechnology, Bicycle, Piper Sandler Companies, MT1-MMP, BTC, Investor, Conference, Cancer research, Drug development, NASDAQ, Thromboxane A2, Pharmaceutical industry

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that management will participate in the following investor conferences in November and December:

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that management will participate in the following investor conferences in November and December:
    Cowens 6th Annual IO Next Summit on Friday, November 11, 2022; fireside chat at 9:10 a.m.
  • Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics.
  • Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials.
  • Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA.

Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 3, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Genentech, Peripheral neuropathy, Journal, Private Securities Litigation Reform Act, Phase, Therapy, Neck, Medicinal chemistry, CD137, Biotechnology, MT1-MMP, BTC, Incidence, U.S. Securities and Exchange Commission, Toxic leukoencephalopathy, Journal of Medicinal Chemistry, COVID-19, Esophageal cancer, Ovary, Head, Research, Molecular Cancer Research, Rash, Clinical trial, Cancer research, Forward-looking statement, Cancer, NASDAQ, American Association for Cancer Research, Non-small-cell lung carcinoma, Drug development, Risk, Program, Technology, Security (finance), Thromboxane A2, SEC, Treatment, Patient, Triple-negative breast cancer, Pharmaceutical industry, Bicycle

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the third quarter ended September 30, 2022 and provided recent corporate updates.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the third quarter ended September 30, 2022 and provided recent corporate updates.
  • We are encouraged by the continued clinical progress across our pipeline, said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics.
  • In September, Bicycle announced top-line results from the Phase I dose escalation portion of its Phase I/II trial of BT5528, a Bicycle Toxin Conjugate (BTC) targeting EphA2, in patients with advanced solid tumors.
  • In June 2022, Bicycle announced the dosing of the first patient in the Phase II dose expansion portion of the Phase I/II trial.

Bicycle Therapeutics Announces Publication of Article in the Journal of Medicinal Chemistry Highlighting Preclinical Data from BT8009 Program

Retrieved on: 
Monday, October 10, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, U.S. Securities and Exchange Commission, American Association for Cancer Research, Molecular Cancer Research, Therapy, Risk, SEC, Bicycle, NASDAQ, Neoplasm, Drug development, Biotechnology, CD137, Security (finance), BTC, Private Securities Litigation Reform Act, Treatment, Cancer research, MT1-MMP, Journal, Clinical trial, Forward-looking statement, Medicinal chemistry, Thromboxane A2, Journal of Medicinal Chemistry, Pharmaceutical industry

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that an article highlighting preclinical data from BT8009, a Nectin-4 targeting Bicycle Toxin Conjugate, was published in the Journal of Medicinal Chemistry.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that an article highlighting preclinical data from BT8009, a Nectin-4 targeting Bicycle Toxin Conjugate, was published in the Journal of Medicinal Chemistry.
  • The article, titled Discovery of BT8009: a Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer is available at the publications section of the Bicycle website at this link .
  • The pre-clinical data published in the Journal of Medicinal Chemistry describe the discovery of our clinical-stage Bicycle Toxin Conjugate candidate targeting Nectin-4 expressing tumors, said Nicholas Keen, Ph.D., Chief Scientific Officer of Bicycle Therapeutics.
  • Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics.

Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT8009 Program in Molecular Cancer Therapeutics

Retrieved on: 
Monday, September 19, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Therapy, COVID-19, MT1-MMP, BTC, Risk, Bicycle, Private Securities Litigation Reform Act, Drug development, Forward-looking statement, U.S. Securities and Exchange Commission, Clinical trial, Thromboxane A2, CD137, NASDAQ, Biotechnology, Molecular Cancer Research, SEC, Cancer research, Security (finance), American Association for Cancer Research, Pharmaceutical industry

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that an article highlighting preclinical data from BT8009, a Nectin-4 targeting Bicycle Toxin Conjugate, was published in Molecular Cancer Therapeutics.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that an article highlighting preclinical data from BT8009, a Nectin-4 targeting Bicycle Toxin Conjugate, was published in Molecular Cancer Therapeutics.
  • The article, titled BT8009: a Nectin-4 targeting Bicycle Toxin Conjugate for treatment of solid tumors is available online via this link .
  • The data published in Molecular Cancer Therapeutics describe BT8009s pre-clinical efficacy in a wide range of cell-derived xenograft and patient-derived xenograft tumor models, with full tumor regression frequently seen in large and small tumors.
  • Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics.

Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors

Retrieved on: 
Wednesday, September 7, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, RECIST, PR, Security (finance), COVID-19, Triple-negative breast cancer, Diarrhea, Safety, Program, Peripheral neuropathy, Immunohistochemistry, Bicycle, Therapy, NASDAQ, Anemia, Rash, Head, Incidence, Toxic leukoencephalopathy, Thromboxane A2, Phase, Neck, Cancer research, Forward-looking statement, SEC, Esophageal cancer, Drug development, Ovary, U.S. Securities and Exchange Commission, IHC, ORR, Biotechnology, Neoplasm, Cancer, ADC, Investor, Risk, Clinical trial, BTC, Ovarian cancer, Private Securities Litigation Reform Act, MT1-MMP, Non-small-cell lung carcinoma, Review, CD137, Patient, DCR, Pharmaceutical industry, Vaccine, Medical imaging

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced Phase I dose escalation top-line results from its Phase I/II trial of BT5528, a BTC targeting EphA2, in patients with advanced solid tumors.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced Phase I dose escalation top-line results from its Phase I/II trial of BT5528, a BTC targeting EphA2, in patients with advanced solid tumors.
  • The therapeutic profile from the dose escalation portion of the Phase I/II trial of BT5528 in patients with late-line disease suggests both differentiated safety and promising activity, most notably in ovarian and urothelial cancers, said Dominic Smethurst, Chief Medical Officer of Bicycle Therapeutics.
  • BT5528, a BTC targeting EphA2, a target for which prior antibody-based approaches have been unsuccessful, has demonstrated anti-tumor activity and differentiated tolerability.
  • Bicycle has established an RP2D dose (6.5mg/m2 every other week) and is enrolling ongoing expansion cohorts.

Bicycle Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Retrieved on: 
Tuesday, September 6, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Bicycle, NASDAQ, Morgan, Thromboxane A2, Drug development, Conference, Biotechnology, Therapy, Investor, Webcast, BTC, MT1-MMP, CD137, Cancer research, Fine chemical

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13th, 2022 at 10:00 a.m.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13th, 2022 at 10:00 a.m.
  • A live webcast of the fireside chat will be accessible in the Investors and Media section of Bicycles Website at www.bicycletherapeutics.com .
  • Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics.
  • Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA.

Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 4, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Cancer research, Private Securities Litigation Reform Act, CD137, Thromboxane A2, Drug development, Annual general meeting, COVID-19, Security (finance), UC, MT1-MMP, Phase, CR, Genentech, ASCO, American Society of Clinical Oncology, Patient, SD, Association, U.S. Securities and Exchange Commission, Society, Program, Biotechnology, AACR, Technology, American Association, Clinical trial, Forward-looking statement, Research, Therapy, SEC, Squamous cell carcinoma, Â, Orange Riots, BTC, Risk, NASDAQ, Fine chemical, Pharmaceutical industry, Health insurance, Bicycle

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the second quarter ended June 30, 2022 and provided recent corporate updates.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the second quarter ended June 30, 2022 and provided recent corporate updates.
  • In June 2022, Bicycle announced that the first patient was dosed in the expansion cohorts of the Phase I/II study of BT5528, Bicycles second-generation Bicycle Toxin Conjugate (BTC) targeting EphA2.
  • Bicycle intends to provide completed results of the dose escalation portion of the clinical trial during the third quarter of 2022.
  • In April 2022, Bicycle announced interim Phase I results from the Phase I/II trial of BT8009, a second-generation BTC targeting Nectin-4.